Isatuximab, Bendamustine, and Prednisone in Refractory Multiple Myeloma

Multiple Myeloma Clinical Trial

Official title:

A Phase I/II Trial of Isatuximab, Bendamustine, and Prednisone in Refractory Multiple Myeloma

Clinical Trial Details — Status: Terminated

Administrative data

• NCT number: NCT04083898
• Other study ID #: 201910194
• Status: Terminated
• Phase: Phase 1
• Start date: April 3, 2020
• Est. completion date: March 7, 2024

Study information

• Verified date: March 2024
• Source: Washington University School of Medicine
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Isatuximab targets and kills CD38-positive myeloma cells in manner similar to rituximab's mechanism of action on CD20-positive lymphoma cells. Based on the synergy between rituximab and bendamustine, as well as the established clinical efficacy of bendamustine and isatuximab as single agents for multiple myeloma, the logical next step is to combine isatuximab with bendamustine and prednisone. Due to lack of effective therapies in refractory multiple myeloma, herein the investigators propose studying this novel combination in this population, in order to address a significant unmet need. The aim of the investigators is to first determine the maximal tolerated dose of the combination in participants with relapsed/refractory myeloma and then to establish the efficacy of this novel combination.

Recruitment information / eligibility

• Status: Terminated
• Enrollment: 15
• Est. completion date: March 7, 2024
• Est. primary completion date: March 13, 2023
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Diagnosis of multiple myeloma with a measurable disease parameter at time of screening. A measurable disease parameter is defined as one or more of the following:

• Serum monoclonal protein = 0.5 g/dL

• 24 hour urine monoclonal protein = 200 mg/24 hour

• Serum free light chain ratio > 5x normal ratio with an absolute difference of 10mg/dL between the involved and uninvolved free light chain

• Soft tissue plasmacytoma = 2 cm measurable by either physical examination and/or applicable radiographs (e.g. MRI, CT, etc.)

• Bone marrow plasma cells = 30%

• Triple-class-refractory disease defined as both of the following:

• Previously received treatment with a proteasome inhibitor, an immunomodulatory drug, and daratumumab, in combination or as single-agents.

• Refractory (defined per IMWG Consensus Criteria as disease that is nonresponsive while on therapy, or progresses within 60 days of last dose) to most recent therapy.

• At least 6 weeks from the last treatment with daratumumab to the first study treatment

• At least 18 years of age.

• Performance status of ECOG = 2 Note: Participants with lower performance status based solely on bone pain secondary to multiple myeloma will be eligible.

• Normal bone marrow and organ function as defined as ALL of the following:

• Absolute neutrophil count = 1500/mm3

• Platelets = 75,000/mm^3 (transfusions not permitted within 7 days of screening)

• ALT (SGPT) and AST (SGOT) < 3.5 x the upper limit of the institutional normal value (ULN).

• Total bilirubin = 2.0 x mg/dL.

• Creatinine clearance > 30 ml/min using Cockcroft-Gault formula

• Females of childbearing potential (FCBP) must agree to refrain from becoming pregnant while on study drug and for 3 months after discontinuation from study drug, and must agree to use adequate contraception including hormonal contraception, (e.g. birth control pills, etc.), barrier method contraception (e.g. condoms), or abstinence during that time frame. Men engaging in sexual intercourse with a FCBP must agree to use adequate contraception including hormonal contraception, (e.g. birth control pills, etc), barrier method contraception (e.g. condoms), or abstinence while on study drug and for 3 months after discontinuation from study drug

• Ability to understand and willing to sign a written informed consent document.

Exclusion Criteria:

• Prior exposure to isatuximab or bendamustine

• History of plasma cell leukemia or MM CNS involvement.

• Receiving renal replacement therapy, hemodialysis, or peritoneal dialysis.

• Diagnosed with another concurrent malignancy requiring treatment.

• Active hepatitis A, B, or C.

• Known intolerance to infused protein products, sucrose, histidine, polysorbate 80 or known hypersensitivity to any of the components of study therapy.

• Receiving any other investigational agents within 14 days prior to enrollment.

• Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, or cardiac arrhythmia.

• Pregnant and/or breastfeeding. Women of childbearing potential must have a negative pregnancy test within 14 days of study entry.

• Patients with HIV are eligible unless their CD4+ T-cell counts are < 350 cells/mcL or they have a history of AIDS-defining opportunistic infection within the 12 months prior to registration. Concurrent treatment with effective ART according to DHHS treatment guidelines is recommended.

Related Conditions & MeSH terms

• Multiple Myeloma
• Neoplasms, Plasma Cell

Intervention

Biological:
• Isatuximab
Isatuximab will be administered on a 28-day cycle

Drug:
• Bendamustine
Bendamustine will be administered on a 28-day cycle as follows
• Prednisone
Prednisone will be administered on a 28-day cycle as follows

Locations

Country	Name	City	State
United States	Washington University School of Medicine	Saint Louis	Missouri

Sponsors (2)

Lead Sponsor	Collaborator
Washington University School of Medicine	Sanofi

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Maximum tolerated dose (MTD) or recommended phase 2 dose (RP2D) of regimen (Phase I only)	The maximum tolerated dose (MTD) is defined as the dose level immediately below the dose level at which 2 participants of a cohort (of 2 to 6 participants) experience dose limiting toxicity (DLT) during the first cycle of treatment. Dose escalation will proceed until the MTD has been reached or until the maximum dose of each drug is tested (Dose Level 3). If no more than 1 DLT is observed at dose levels 1, 2 and 3, level 3 will be declared the recommended phase II dose (RP2D) and the MTD will remain undefined.	Completion of first cycle of treatment for all participants enrolled in Phase I portion (estimated to be 9 months)
Primary	Overall response rate (ORR) (Phase II only)	-ORR defined as the proportion of patients meeting the criteria for partial response, very good partial response, complete response, or stringent complete response per IMWG 2016 response criteria.	6 months
Secondary	Number of adverse events experienced by participants (Phase I and Phase II)	Participants will be evaluated for toxicity according to the Common Terminology Criteria for Adverse Events (CTCAE) of the National Cancer Institute (NCI) version 5.0.	From start of treatment through 30 days after completion of treatment or initiation of new anti-myeloma therapy, whichever occurs first (estimated to be 7 months)
Secondary	Progression-free survival (PFS) (Phase II only)	Progression-free survival (PFS) will be defined as time from Cycle 1 Day 1 to disease progression or relapse. Any patient who expires, withdraws, or is lost to follow-up prior to disease progression or relapse will be censored at last follow-up. Patients who are removed from study therapy prior to progression or relapse will be censored at the time of initiation of subsequent anti-myeloma treatment.	Up to 5 years after removal from study (estimated to be 5 years and 6 months)
Secondary	Overall survival (OS) (Phase II only)	Overall survival (OS) will be defined as time from Cycle 1 Day 1 to death due to any causes. Patients who are alive at the time of data analyses will be censored on the last known alive date. Patients who are removed from study therapy prior death will be censored at the time of initiation of subsequent anti-myeloma treatment.	Up to 5 years after removal from study (estimated to be 5 years and 6 months)

External Links

•   Alvin J. Siteman Cancer Center at Barnes-Jewish Hospital and Washington University School of Medicine